Aritinercept NCT07596901 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1/2

Clinical phase

Recruiting

Recruitment status

81

Planned enrollment

2029-03-02

Primary-completion proxy

Executive view

NCT07596901 evaluates Aritinercept in Myasthenia Gravis. The disclosed sponsor is Aurinia Pharmaceuticals, Inc., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is To assess the safety and tolerability of aritinercept: Incidence of treatment-emergent adverse events, assessed over Baseline to study completion, up to 73 weeks.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07596901 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Myasthenia Gravis landscape. Drug & Asset MCP drug_fetch was queried for Aritinercept, while Company & Deal Intelligence MCP organization_fetch was queried for Aurinia Pharmaceuticals, Inc..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07596901	Aritinercept	Phase 1/2 / Recruiting	Aurinia Pharmaceuticals, Inc.	United States	To assess the safety and tolerability of aritinercept: Incidence of treatment-emergent adverse events Baseline to study completion, up to 73 weeks	2029-03-02
NCT07714798	Universal STAR-T Cell(BriSTAR Immunotech)	Phase 1 / Not yet recruiting	Huazhong University of Science Tongji Hospital, Tongji Medical College	China	Type, severity, and frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs). AEs observation will be follow-up for 24 weeks. The observation perio…	2027-07-06
NCT07676266	C-CAR168	Phase 1 / Not yet recruiting	The Affiliated Hospital of Qingdao University	China	Incidence and severity of Adverse Events [Safety and Tolerability] Throughout the first 3 months follow up period completion	2027-11-01
NCT07673744	Ublituximab	Phase 2 / Recruiting	TG Therapeutics, Inc.	United States	Time to Onset of a Clinical Worsening Event Up to Week 24	2028-07-01
NCT07647510	Claseprubart	Phase 3 / Recruiting	Dianthus Therapeutics, Inc.	United States	Change from Baseline to Week 17 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score Baseline (Day 1) to Week 17	2028-12-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07596901 is a Phase 1/2, recruiting study with 81 planned participants. Allocation is Randomized, masking is Quadruple, and the intervention model is Sequential Assignment.

The primary endpoint is “To assess the safety and tolerability of aritinercept: Incidence of treatment-emergent adverse events” over “Baseline to study completion, up to 73 weeks.” No additional primary-endpoint description was returned in the selected field set.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 81 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

The protocol identifies Aritinercept as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Myasthenia Gravis. These records do not establish direct evidence for NCT07596901 unless the registration number matches.

A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholi…

Phase 3; n=119; MG-ADL Total Score Change From Baseline(Least Squares Mean) = -1.90 points on a scale (90% Confidence Interval, -2.51 to -1.28); MG-ADL Total Score Change From Baseline(Least Squares Mean) = -3.35 points on a scale (90% Confidence Interval, -3.98 to -2.72) Source: https://clinicaltrials.gov/ct2/show/results/NCT06298552

Assessment of sustained health- related quality of life in Phase 3 Vivacity-MG3 Trial of Nipocalimab versus Placebo in Generalized Myasthenia Gravis

Phase 3; n=129; EQ-5D-VAS(24-week) = 37.1 % ; EQ-5D-VAS(24-week) = 55.2 % Source: https://onlinelibrary-wiley-com.sutd.idm.oclc.org/journal/14681331

Investigating intravenous efgartigimod in juvenile generalized myasthenia gravis: Results from the ADAPT JR study

Phase 2/3; n=11; MSE(Cycle 1) = 72.7 % Source: https://onlinelibrary-wiley-com.sutd.idm.oclc.org/journal/14681331

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Aritinercept is indexed as Fc fusion protein with APRIL x BAFF biology and a global stage of Phase 1/2. The asset profile lists Thunderbolt Pharma, Inc. as an originator or developer.

No exact Company & Deal Intelligence profile was returned for Aurinia Pharmaceuticals, Inc.. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Aritinercept is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07596901
Protocol source: https://clinicaltrials.gov/study/NCT07596901
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.

Aritinercept in Myasthenia Gravis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes To assess the safety and tolerability of aritinercept: Incidence of treatment-emergent adverse events and 2029-03-02 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP